The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 31 of the 53 sources its claims cite were checked for support.
Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients
Open accessAbstract
Age-related macular degeneration (AMD) is a vision threatening disease in older adults. Anti-VEGF treatment is effective for the majority of neovascular AMD (nAMD) patients, although approximately 30% of nAMD patients have an incomplete response for unknown reasons. Here we assessed the contribution of single nucleotide polymorphisms (SNPs) in key angioinflammatory regulatory genes in nAMD patients with an incomplete response compared to those responsive to anti-VEGF treatment. A total of 25 responsive and 30 nAMD patients with an incomplete response to anti-vascular endothelial growth factor (anti-VEGF) treatment were examined for known SNPs that impact the structure and function of thromobospondin-1 (TSP1), Bcl-2-interacting mediator of cell death (BIM) and complement factor H (CFH). Plasma levels of C-C motif chemokine ligand 2 (CCL2/MCP1), TSP1 and VEGF were assessed by ELISA. Patients responsive to anti-VEGF treatment showed a significant increase in the TSP1 rs2228262 AA allele and a trend for the BIM (rs724710) CT allele. Consistent with previous reports, 42% of the patients responsive to anti-VEGF expressed the CC allele for CFH rs1061170. Although the CFH TT allele had similarly low prevalence in both groups, the TC allele tended to be more prevalent in patients with an incomplete response. Patients with an incomplete response also had increased plasma CCL2/MCP1 levels, consistent with the role increased inflammation has in the pathogenesis of nAMD. Our studies point to new tools to assess the potential responsiveness of nAMD patients to anti-VEGF treatment and suggest the potential use of anti-CCL2 for treatment of nAMD patients with an incomplete response to anti-VEGF.
Overview
CoChat Summary
TL;DR
In nAMD patients, the TSP1 rs2228262 AA allele was significantly more frequent among anti-VEGF responders, while incomplete responders had higher plasma CCL2/MCP1. The authors suggest TSP1/BIM/CFH polymorphisms and CCL2/MCP1 may help assess anti-VEGF responsiveness and that anti-CCL2 therapy warrants study.
Key findings
- TSP1 rs2228262 AA allele was significantly increased in responsive patients: 88% (22/25) vs 67% (20/30) in incomplete responders; no responsive patient had the GG allele. The odds of response were 5-fold greater for homozygous wildtype A carriers (OR = 5.00, 95% CI 1.03–32.00; PD = 0.97), with 68% (95% CI 37%–89%) vs 31% (95% CI 8%–63%) estimated to respond.
- BIM rs724710 showed a trend: the CT allele was more common in responders (53% vs 30%), while incomplete responders tended to have the CC allele. Homozygous CC had lower odds of response (OR = 0.41, 95% CI .012–1.30; PD = 0.93).
- CFH rs1061170 CC was present in 42% of responsive patients vs 33% of incomplete responders; TT prevalence was similarly low in both groups, and TC tended to be more prevalent in incomplete responders.
- Incomplete responders had significantly increased plasma CCL2/MCP1; VEGF trended higher but did not reach significance, and TSP1 plasma levels were similar between groups. Choroidal endothelial cells lacking TSP1 showed increased CCL2/MCP1, IL6, and IL1β expression.
Methods
- Blood samples from 25 anti-VEGF-responsive and 30 incomplete-response nAMD patients were genotyped for TSP1 rs1478604 and rs2228262, BIM rs724710, and CFH rs1061170 by Sanger sequencing or TaqMan qPCR. Responsiveness was defined by absence of intraretinal/subretinal fluid on OCT after 1 year; incomplete response by persistent fluid after 1 year.
- Plasma CCL2/MCP1, VEGF, and TSP1 were measured by ELISA. Murine wild-type and TSP1−/− choroidal endothelial cells were analyzed by qPCR for MCP-1, IL-6, and IL-1β.
- Genetic associations used dominant, recessive, and co-dominant models with Bayesian logistic regression, reporting odds ratios, 95% highest density credible intervals, and probability of direction; sensitivity analysis used Jensen-Shannon distance.
Limitations
- The paper states the study had a moderate sample size, took place during the COVID pandemic which restricted patient access and participation, and that sex and age covariates were removed due to sub-optimal model fit.
- The paper states that TSP1 rs2228262 recessive and co-dominant models showed prior sensitivity with low likelihood sensitivity, indicating not enough observations for reliable comparisons in those models.
- Evident from the text: many findings are trends rather than significant associations, the cohort is small and from a single Wisconsin clinic, and no replication cohort is reported.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
23 Valid · 1 Not valid · 7 Not checked · 57 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Our recent preclinical studies showed that mice lacking Bim expression are unable to effectively clear mononuclear phagocytes leading to increased subretinal fibrosis and scarring during CNV [25].”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Introduction
What the sources say
- Partly supportedcites [25] S Wang, 2022, Bim Expression Promotes the Clearance of Mononuclear Phagocytes during Choroidal Neovascularization, Mitigating Scar Formation in Mice, Life sourceExperimental — accuracy not yet measured
Results §2.6 reports reduced phagocyte clearance and increased collagen I staining in the choroid of Bim-deficient mice after laser-induced CNV. Results §2.7 and the Discussion describe delayed clearance and scarring as associated or correlated, rather than establishing that one causes the other. The measured scarring was choroidal; the passages do not specifically establish subretinal fibrosis. (LLM, conf=0.86)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Decreased TSP1 expression exacerbates ocular neovascularization [12].”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Introduction
What the sources say
- Partly supportedcites [12] S Wang, 2012, Lack of thrombospondin 1 and exacerbation of choroidal neovascularization, Arch Ophthalmol sourceExperimental — accuracy not yet measured
The Results section (‘TSP1-deficiency results in increased areas of CNV’) reports substantially larger laser-induced choroidal neovascular lesions in mice lacking TSP1. The claim extends that finding from complete TSP1 deficiency to decreased expression generally, and from choroidal neovascularization to ocular neovascularization broadly; those extensions were not tested here. (LLM, conf=0.82)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“BIM polymorphisms that decrease BIM expression are well known to cause patient resistance to many conventional cancer treatments including anti-VEGF [26–28].”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Introduction
What the sources say
- Partly supportedcites [26] O Naik E, 2011, Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells, J Exp Med sourceExperimental — accuracy not yet measured
The Results and Discussion sections report that Bim loss prevented the tumor-growth inhibition seen with anti-VEGF treatment in mice. The authors suggest that BIM or related polymorphisms may affect patients’ treatment responses, but they do not show that polymorphisms decrease BIM expression or establish that they cause patient resistance to anti-VEGF or many conventional cancer treatments. Page numbers are unavailable in our copy. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [27] KP Ng, 2012, A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nat Med source
- Partly supportedcites [28] AF Cardona, 2016, BIM deletion polymorphisms in Hispanic patients with non-small cell lung cancer carriers of EGFR mutations, Oncotarget sourceExperimental — accuracy not yet measured
The Introduction (page unavailable) describes BIM deletion polymorphisms as producing isoforms lacking the proapoptotic BH3 domain, not as simply decreasing BIM expression. The Results and Discussion (pages unavailable) associate the deletions with poorer response to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer. They do not establish that the polymorphisms cause resistance to many conventional treatments or to anti-VEGF therapy. (LLM, conf=0.87)
boostedstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“complement factor H (CFH) polymorphisms, a risk factor for nAMD, attenuates TSP1 interaction with its receptor (CD47) on mononuclear phagocytes delaying their clearance [18, 19].”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Introduction
What the sources say
- Partly supportedcites [18] B Calippe, 2017, Complement Factor H Inhibits CD47-Mediated Resolution of Inflammation, Immunity sourceExperimental — accuracy not yet measured
The Results (page unavailable) show that CFH interfered with TSP-1 activation of CD47 and delayed subretinal mononuclear-phagocyte elimination. They specifically found that the AMD-associated CFH(H402) variant inhibited microglial-cell clearance more strongly than CFH(Y402), but the two variants had similar effects on bone-marrow monocytes. The claim overgeneralizes this variant-specific finding to CFH polymorphisms and mononuclear phagocytes broadly; the Discussion also presents physical hindrance of TSP-1 binding as a possible mechanism, not an established interaction change. (LLM, conf=0.86)
- Partly supportedcites [19] B Calippe, 2014, Complement factor H and related proteins in age-related macular degeneration, Comptes rendus biologies sourceExperimental — accuracy not yet measured
The genetic studies section (p. 3) links CFH polymorphisms to AMD risk, and the pathomechanistical discussion (p. 4) describes a proposed link between CFH binding and impaired phagocytosis of debris. Neither passage supports the specific claim that CFH polymorphisms weaken TSP1–CD47 interaction on mononuclear phagocytes or delay clearance of those cells; searches for CD47, TSP1 and delayed clearance found no such passage. (LLM, conf=0.83)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“with higher basal BIM expression reported in individuals having this CC allele [27, 33].”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Discussion
What the sources say
- Not checked — no full text of the sourcecites [27] KP Ng, 2012, A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer, Nat Med source
- Supportedcites [33] V Augis, 2013, A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib, PLoS One source
The Results section identifies c465C>T as the synonymous SNP rs724710 and reports that the T allele was associated with reduced basal Bim mRNA expression in blood mononuclear cells from healthy controls. Figure 3 compares C/C with C/T and T/T genotypes, supporting the reported higher expression for C/C; the measurement was of mRNA, not protein. (LLM, conf=0.93)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
37 more claims · 5 with their cited sources checked
Create a free account to see all 88 claims and every source verdict.
- Probably not a substantial claim. 25
- It may state two separate claims as one. 27
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The largest body of evidence on genetic variants associated with treatment response is related to ARMS2/HTRA1, CFH, and VEGFA,6,10,17–19 but even here results are conflicting.”
From ANO2 Genetic Variants and Anti-VEGF Treatment Response in Neovascular AMD: A Pharmacogenetic Substudy of VIEW 1 and VIEW 2 (2024) · cites this paper as [19]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Discussion
“Only had one patient in the responsive and 3 in the incomplete response group that had the minor CC allele SNP rs1478604.”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > Thrombospondin-1 polymorphisms
“| rs1478604 | TSP1 | C | 2 | 8 | 4 | 14 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > BIM polymorphisms
“OR = 0.41, 95% CI = .012–1.30, PD = 0.93”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > Thrombospondin-1 polymorphisms
“| BIM rs724710 (C/T) | Dominant | C vs T+CT | 0.41 | [0.12, 1.30] | 0.93 |”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| rs724710 | BIM | C/T | 13 | 53 | 9 | 30 |”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > Thrombospondin-1 polymorphisms
Reported 53 · recomputed 52
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| rs724710 | BIM | T | 3 | 17 | 4 | 13 |”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > Thrombospondin-1 polymorphisms
Reported 17 · recomputed 12
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > BIM polymorphisms
“9 of 12 patients with Bim CT allele”
§ Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients > Results > Thrombospondin-1 polymorphisms
“| rs724710 | BIM | C/T | 13 | 53 | 9 | 30 |”
1 more finding
Create a free account to see every finding of this check.
Citations
Cites
Complement factor H polymorphism in age-related macular degeneration
Klein, R. J., Zeiss, C., Chew, E. Y., Tsai, J.-Y., Sackler, R. S., Haynes, C., Henning, A. K., SanGiovanni, J. P., Mane, S. M., Mayne, S. T., et al. (2005) · Science · doi:10.1126/science.1109557 · Cited by 4,492
Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele
Carmeliet, P., Ferreira, V., Breier, G., Pollefeyt, S., Kieckens, L., Gertsenstein, M., Fahrig, M., Vandenhoeck, A., Harpal, K., Eberhardt, C., et al. (1996) · Nature · doi:10.1038/380435a0 · Cited by 4,117
Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene
Ferrara, N., Carver-Moore, K., Chen, H., Dowd, M., Lu, L., O'Shea, K. S., Powell-Braxton, L., Hillan, K. J., & Moore, M. W. (1996) · Nature · doi:10.1038/380439a0 · Cited by 3,628
Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration
Heier, J. S., Brown, D. M., Chong, V., Korobelnik, J.-F., Kaiser, P. K., Nguyen, Q. D., Kirchhof, B., Ho, A., Ogura, Y., Yancopoulos, G. D., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.09.006 · Cited by 2,485
Complement factor H variant increases the risk of age-related macular degeneration
Haines, J. L., Hauser, M. A., Schmidt, S., Scott, W. K., Olson, L. M., Gallins, P., Spencer, K. L., Kwan, S. Y., Noureddine, M., Gilbert, J. R., et al. (2005) · Science · doi:10.1126/science.1110359 · Cited by 2,424
Age-related macular degeneration
Jager, R. D., Mieler, W. F., & Miller, J. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0801537 · Cited by 1,379
FERRARA, N., DAMICO, L., SHAMS, N., LOWMAN, H., & KIM, R. (2006) · Retina · doi:10.1097/01.iae.0000242842.14624.e7 · Cited by 849
Risk of geographic atrophy in the comparison of age-related macular degeneration treatments trials
Grunwald, J. E., Daniel, E., Huang, J., Ying, G.-S., Maguire, M. G., Toth, C. A., Jaffe, G. J., Fine, S. L., Blodi, B., Klein, M. L., et al. (2014) · Ophthalmology · doi:10.1016/j.ophtha.2013.08.015 · Cited by 590
Self-citationNg, K. P., Hillmer, A. M., Chuah, C. T. H., Juan, W. C., Ko, T. K., Teo, A. S. M., Ariyaratne, P. N., Takahashi, N., Sawada, K., Fei, Y., et al. (2012) · Nature Medicine · doi:10.1038/nm.2713 · Cited by 557
The Prior Can Often Only Be Understood in the Context of the Likelihood
Gelman, A., Simpson, D., & Betancourt, M. (2017) · Entropy · doi:10.3390/e19100555 · Cited by 454
Cited by
Insights into eye genetics and recent advances in ocular gene therapy
Szabó, V., Varsányi, B., Barboni, M. T. S., Takács, Á. I., Knézy, K., Molnár, M. J., Nagy, Z. Z., György, B., & Rivolta, C. (2025) · Molecular and Cellular Probes · doi:10.1016/j.mcp.2025.102008 · Cited by 16
Guymer, R. H., Silva, R., Ghadessi, M., Leal, S., Gashaw, I., Damask, A., Paulding, C., & Rittenhouse, K. D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.8.17 · Cited by 6
“6,10,17 The largest body of evidence on genetic variants associated with treatment response is related to ARMS2/HTRA1 , CFH , and VEGFA , 6,10,17–19 but even here results are conflicting.”
Thrombospondins: Conserved mediators and modulators of metazoan extracellular matrix
Adams, J. C. (2024) · International Journal of Experimental Pathology · doi:10.1111/iep.12517 · Cited by 4
“…of autoimmune dry eye syndrome [243] rs2228262 Over-represented in patients responsive to anti-VEGF therapy for age-related macular degeneration [244] rs2228262 Association with hereditary primary open-angle glaucoma and increased intraocular pressure [245] Missense alleles Correlation with…”
Bcl-2-Dependent Persistence of Mononuclear Phagocytes Promotes Ocular Fibrosis
Song, Y., Wang, S., Darjatmoko, S. R., Sheibani, N., & Sorenson, C. M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167455
“We also recently showed that polymorphisms or mutations that reduce Bim levels and/or activity could contribute to the noted lack of response to anti-VEGF treatment in patients with nAMD [48].”
Self-citation
Metadata
- Authors
- Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N.
- Affiliations
- University of Wisconsin–Madison (US)
- Corresponding author
- Sorenson, Christine M.
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2024-02-26
- Volume
- 19
- Issue
- 2
- Pages
- e0297135
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC10896504
- OpenAlex
- W4392160831
- Cited by
- 5
- References
- 51
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 2
- FWCI
- 1.97
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- ICTR
- UW Center for Human Genomics and Precision Medicine
- Pat and Jay Smith Macular degeneration treatment innovation program
- Research to Prevent Blindness
- Retina Research Foundation
- NIH (P30 CA014520, EY030076, P30EY016665)
- Lions Gift of Sight (Wisconsin)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- neovascular age-related macular degeneration, thrombospondin-1, building information modeling, complement factor H, single nucleotide polymorphisms, inflammation, genetic susceptibility, vascular endothelial growth factor
- MeSH terms
- Aged, Humans, Visual Acuity, Complement Factor H, Thrombospondins, Angiogenesis Inhibitors, Polymorphism, Single Nucleotide, Vascular Endothelial Growth Factor A, Wet Macular Degeneration
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. https://app.cochat.ai/papers/10.1371/journal.pone.0297135
- The paper
- Sorenson, C. M., Gurel, Z., Song, Y.-S., Peterson, K. D., Blodi, B. A., & Sheibani, N. (2024). Thrombospondin-1, BIM and CFH polymorphisms and response to anti-VEGF treatment in neovascular age- related macular degeneration patients. PLOS ONE. https://doi.org/10.1371/journal.pone.0297135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.